An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A Reddit post asked why people using GLP-1 drugs (the class that includes weight-loss medicines like semaglutide) often report they can still enjoy smoking cannabis but suddenly find alcohol much less appealing. The post didn’t link to a specific study, so this is a general explanation based on what researchers and doctors have observed so far, not a report of a single definitive experiment. GLP-1 drugs are medications that copy a natural hormone made in the gut. That hormone helps control appetite and blood sugar by sending signals to the brain that you’re full and by slowing how fast the stomach empties. Semaglutide and similar medicines are often called GLP-1 receptor agonists (that just means they activate the same receptor the natural hormone uses). People commonly take them to lose weight or to treat diabetes. What we actually know about how GLP-1 drugs change the appeal of substances like alcohol or cannabis comes from a mix of animal studies, small human reports, and lots of patient anecdotes. In animals, activating GLP-1 receptors tends to reduce alcohol consumption and the rewarding feelings from alcohol. A few small human studies and many people taking the drugs report decreased desire for or enjoyment of alcohol. The evidence for cannabis is weaker: there aren’t strong controlled studies showing GLP-1 drugs boost the desire for cannabis. Many patients simply say they can still smoke or that weed feels about the same, which could reflect different brain pathways for alcohol versus cannabis. Why might this matter? If GLP-1 drugs reduce alcohol’s appeal, that could help people who drink heavily or are trying to cut back while on these medications. It’s also useful for doctors and patients to know what to expect: someone starting a GLP-1 drug might find they’re less drawn to drinking, while their social use of cannabis might not change. That can affect social plans, safety considerations, and conversations about substance use during weight-loss treatment. There are important caveats. The evidence isn’t large or definitive for humans, and individual responses vary a lot. GLP-1 drugs have side effects like nausea, upset stomach, and, rarely, more serious problems; they should be used under medical supervision. Mixing substances always carries risks — for example, drinking while having nausea or altered metabolism might be unpleasant or unsafe. Also, recreational cannabis and alcohol affect the brain differently, so it’s not surprising they interact differently with any medication. If someone notices big changes in their cravings or substance use on a GLP-1 drug, they should discuss it with their doctor. Bottom line: early science and many patient reports suggest GLP-1 drugs often blunt the appeal of alcohol but don’t clearly change cannabis use, though the evidence is limited and personal experiences vary.
Source: r/Semaglutide